NYSE$STE

STERIS PLC · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

STERIS's Q4 2021 financial results were announced, with revenue increasing by 6% and adjusted EPS remaining flat year-over-year. The company also provided its outlook for fiscal year 2022, including the impact of the Cantel Medical acquisition.

STERIS plc reported a 6% increase in revenue to $873.5 million for the fourth quarter of fiscal year 2021, driven by growth in all three segments. Net income was $87.4 million, or $1.02 per diluted share, while adjusted net income was $140.3 million, or $1.63 per diluted share.

  • Fourth quarter revenue increased 6% as reported.
  • Constant currency organic revenue increased 0.3%.
  • Net income for the fourth quarter was $87.4 million, or $1.02 per diluted share.
  • Adjusted net income for the fourth quarter was $140.3 million, or $1.63 per diluted share.

Headline financials

Total Revenue

$874M

Previous: $823M+6.1%
EPS (adj)

$1.63

Previous: $1.64-0.6%
Const. Curr. Organic Growth

0.3%

Previous: 8.0%-96.3%
Capital Expenditures

$74.8M

Previous: $60.9M+22.8%
Free Cash Flow

$113M

Previous: $138M-18.3%
Net Income

$87.4M

Previous: $123M-29.1%
Operating Income

$144M

Previous: $158M-8.6%
Gross Profit

$380M

Previous: $364M+4.3%
Cash & Equivalents

$221M

Previous: $320M-31.0%
Total Assets

$6.57B

Previous: $5.43B+21.2%
Stock-Based Comp

$6.04M

Previous: $4.95M+22.1%

Revenue & EPS history

STERIS · Revenue · Quarterly

$874M

Q4 2021+6.1%vs Q4 2020
Beat estimate in 15 of 16 quarters(94%)
ActualEstimate

Revenue by segment

STERIS · $1.59B total across 3 segments · Q4 2027

  • Healthcare
    $1.14B
  • Applied Sterilization Technologies
    $289M
  • Life Sciences
    $163M

Forward guidance

STERIS expects as reported revenue of approximately $4.5 billion for fiscal 2022. Constant currency organic revenue growth is expected to be in the range of 8-9%. Adjusted earnings per diluted share are anticipated to be in the range of $7.40 - $7.65.

Tailwinds

  • As reported revenue of approximately $4.5 billion.
  • Constant currency organic revenue growth is expected to be in the range of 8-9%.
  • Currency movements are anticipated to be favorable to revenue by approximately $15 million.
  • Adjusted earnings per diluted share are anticipated to be in the range of $7.40 - $7.65.
  • Free cash flow for fiscal 2022 is expected to be approximately $380 million.

Headwinds

  • Integration and deal related costs primarily for the purchase of Cantel Medical are expected to be approximately $200 million.
  • Capital spending is anticipated to be approximately $320 million for the combined company.
  • The failure to obtain Cantel stockholder approval of the proposed transaction.
  • The possibility that the closing conditions to the proposed transaction may not be satisfied or waived.
  • Delay in closing the proposed transaction or the possibility of non-consummation of the proposed transaction.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

+0.5%

Avg return

Earnings day

+1.0%

Avg return

5 days after

+1.3%

Avg return

30 days after

59%

38 / 64 earnings

Positive

+12.9%

Q4 2014

Best reaction

-11.4%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2027+0.0%+7.2%+2.8%
Q3 2026-7.7%-7.4%-12.8%
Q2 2026+7.0%+9.7%+8.3%
Q4 2025+8.6%+10.1%+6.1%
Q3 2025+2.1%+1.1%+5.4%
Q2 2025-5.2%-2.5%-5.1%
Q1 2025-1.8%-0.8%+0.5%
Q4 2024+6.2%+9.2%+6.6%
Q3 2024-2.5%-0.4%+3.4%
Q2 2024-5.1%-8.4%-7.1%
Q1 2024+1.0%+0.2%+1.8%
Q4 2023+11.2%+12.7%+10.6%
Q3 2023-11.4%-9.5%-18.2%
Q2 2023+3.5%+2.6%+17.3%
Q1 2023-8.8%-4.7%-10.0%
Q4 2022+1.4%+1.2%+2.6%
Q3 2022+4.6%+1.3%-2.1%
Q2 2022-5.5%-4.8%-6.4%
Q1 2022+0.6%+1.2%+0.2%
Q4 2021-3.6%-3.1%+1.9%
Q3 2021-1.9%-1.7%-8.1%
Q2 2021-0.5%+2.5%+8.8%
Q1 2021-1.0%-3.4%+2.5%
Q4 2020+1.2%+7.0%+1.8%
Q3 2020+6.1%+10.2%-5.0%
Q2 2020+2.3%+2.6%+8.4%
Q1 2020+3.0%+4.1%+3.0%
Q4 2019+1.1%+3.2%+10.2%
Q3 2019+1.9%+3.1%+3.6%
Q2 2019+7.0%+7.4%+5.4%
Q1 2019-0.7%-1.1%-1.9%
Q4 2018+4.7%+4.6%+8.6%
Q3 2018-4.7%-2.8%+7.8%
Q2 2018-6.0%-6.6%-3.9%
Q1 2018+4.9%+3.3%+5.8%
Q4 2017+1.4%-0.4%+6.4%
Q3 2017-6.5%-5.7%-3.4%
Q2 2017-3.0%+0.5%-2.0%
Q1 2017-1.6%-1.9%-2.0%
Q4 2016-0.5%
Q3 2016-1.9%
Q2 2016+6.4%
Q1 2016+0.7%
Q4 2015+2.5%
Q3 2015+1.1%
Q2 2015+3.5%
Q1 2015+0.3%
Q4 2014+12.9%
Q3 2014+0.5%
Q2 2014-3.6%
Q1 2014-3.6%
Q4 2013+8.3%
Q3 2013+1.4%
Q1 2013+1.4%
Q2 2013+1.1%
Q4 2012-0.3%
Q3 2012+0.8%
Q1 2012+0.8%
Q2 2012-4.4%
Q4 2011+0.3%
Q3 2010+0.2%
Q1 2010+0.2%
Q2 2010+0.8%
Q4 2010-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro